Participated · Equity · Jan 2025

hc1 uses advanced data management, analytics, workflow automation and AI to turn diagnostic lab data into actionable insights that improve diagnoses and operational performance. The company completed an acquisition of healthcare performance consulting firm Accumen in October 2024 and markets the combined hc1 + Accumen platform. According to the release, thousands of health systems and labs leverage its technology and consultative services to care for nearly 100 million patients, and the company has over a decade of experience. The $6.25 million financing announced in January 2025 will support launching enhanced solutions that couple hc1 and Accumen’s technology and expertise. Product and operational priorities highlighted include lab stewardship, optimizing blood management and anemia care, eliminating supply chain waste, and improving lab outreach to drive profitable growth for health systems. The company positions these initiatives as advancing predictive insights, personalized care, and increased efficiencies across the care continuum. hc1.com provides a HIPAA-compliant healthcare CRM and analytics platform certified as an AWS Healthcare Competency solution. Its platform has been adopted across more than 1,200 lab, post-acute care, and provider locations and has organized over 5.2 billion clinical transactions into 52 million unique anonymous consumer profiles. The company offers information services including hc1 ProviderView™ and the hc1 Opioid Dashboard to drive personalized, high-value care and provider engagement. hc1 has been recognized as a top-rated healthcare CRM by Frost & Sullivan and counts organizations such as Cleveland Clinic and Nationwide Children’s Hospital among users. The company plans to accelerate development of its healthcare relationship management solutions, expand its team, and increase adoption of its information services. HC1 provides a scalable, cloud-based platform that ingests clinical and business data to help labs, pharmacies, physicians and health systems track business relationships and improve patient engagement. Its product is used to prompt follow-up actions (for example, identifying why a patient missed an appointment) and to coordinate multiparty communication across care teams. The company sees large near-term opportunities in diagnostics and potential future uses including aiding therapeutic discovery and identifying specimen errors. HC1 partners with technology providers such as IBM Watson to generate patient insights and reduce administrative burden through AI-powered tools. Its business model charges customers based on usage, and management plans to expand direct sales and strategic partnerships while adding sales and marketing staff. Financially, HC1 recently raised capital and credit to support this growth push, including a $13.2M financing and a $5M revolving credit facility.

Led · Series G · Apr 2023

Epic Sciences develops and markets liquid‑biopsy diagnostics to guide therapy selection and monitor disease progression in prostate and breast cancers. Its flagship offering, DefineMBC, is a three‑component blood‑based biopsy that reports circulating tumor cell detection, HER2 and ER protein expression and single‑cell sequencing for ERBB2 amplification, alongside a 56‑gene plasma cell‑free DNA panel including ERBB2 and PIK3CA and tumor mutational burden. The company leverages proprietary cell analysis and cell‑free analysis in a CAP/CLIA‑accredited laboratory and provides Comprehensive Cancer Profiling to pharmaceutical partners and major cancer centers. Epic has delivered DefineMBC results to 700 patients and their oncologists through a Clinical Experience Program. In the past twelve months Epic raised $67 million across a $43M Series F and a $24M Series G to fund commercialization of DefineMBC. Proceeds are being used to build commercial infrastructure (sales, product marketing, customer service, medical affairs, payer markets and billing) and to generate additional concordance and outcomes data. Epic Sciences is a diagnostics company based in San Diego that develops and markets liquid biopsy tests and multi-omic cancer profiling to guide therapy selection and monitor disease progression in prostate and breast cancers. Its liquid biopsy platform combines proprietary cell analysis capabilities with cell-free DNA analysis to provide more complete, efficient cancer profiling. The company operates a full-service CAP/CLIA-accredited laboratory and provides research support services, partnering with pharmaceutical companies and major cancer centers worldwide. Epic's DefineMBC™ blood-based test for comprehensively characterizing metastatic breast cancer has been reporting patient results since April 2022 and uses multi-analyte methods to detect circulating tumor cells, assess protein expression (HER2, ER), determine intra-cell CNVs, and identify SNVs, indels, fusions, CNVs, MSI and TMB from plasma. The company plans to use the new capital to continue advancing its multi-omic platform and to expand operations in single-cell sequencing and data analytics infrastructure. Lloyd Sanders serves as President and CEO. Epic Sciences develops diagnostics and decision-support analytics that match patients’ individual cancer cells to individualized drug therapies using computer vision and machine learning. The company’s technology is aimed at prolonging life and reducing treatment costs by avoiding ineffective therapies. Epic is advancing oncology decision-support services in its pipeline and plans to accelerate clinical studies to validate and commercialize those offerings. Proceeds from the recent financing are expected to fund those clinical studies and support execution of its long-term growth plan. Epic is based in San Diego and positions its products for value-based, individualized cancer care. Epic Sciences, based in San Diego, develops blood-based liquid biopsy tests designed to predict drug response in cancer patients. Its core platform is the proprietary No Cell Left Behind technology and a portfolio of blood-based tests that characterize rare circulating cells using digital imaging and big data analytics. The company plans to use the funds to accelerate clinical studies for oncology tests in its pipeline and to enhance No Cell Left Behind to include characterization of rare leukocyte cell populations. These enhancements are intended to drive transformative insights into the cellular drivers of response or resistance to key drug classes such as immuno-oncology therapies. Epic recently partnered with Genomic Health to commercialize the OncotypeDx AR-V7 Nucleus Detect test and to leverage Genomic Health’s commercial channel and enterprise systems. Murali Prahalad, Ph.D., serves as president and CEO. Epic Sciences develops technology that enables comprehensive characterization of circulating tumor cells (CTCs) from a liquid biopsy to inform therapy selection and detect early signs of drug resistance. The company is led by Murali Prahalad, Ph.D., president and CEO. Epic offers products and offerings aimed at personalizing and advancing the treatment and management of cancer. The company expanded available capital under an existing credit facility, giving it optionality to accelerate expansion of research capabilities and product development efforts. The amended credit facility increases available capacity and extends the financing maturity, improving near‑term liquidity and runway for R&D. Epic is a private diagnostics company based in San Diego, CA.